Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.
1 The State Education Ministry Laboratory of Developmental Genes and Human Disease, the Provincial Key Laboratory of Gene Diagnosis and Therapy, Southeast University Medical School, Nanjing 210009, Jiangsu Province, China
2 Department of Medicine, Medical University of South Carolina, Charleston, SC 284253
3 Department of Medical Microbiology, Immunology, and Cell Biology, Cancer Institute, Southern Illinois University School of Medicine, 911 North Rutledge Street, Springfield, IL 62702
Abstract
Aldo-keto reductase (AKR) is a super gene family, consisting of fourteen families and more than 40 members overall. These proteins have been well known as metabolic enzymes of carbonyls, but recent data indicates that the members in AKR families 1 and 7 (AKR1 & AKR7) are involved in the development of some human and rodent tumors, such as in primary liver, lung, colorectal, prostate, and breast cancers. They are involved in the pathogenesis, diagnosis, and therapy of these tumors. This manuscript discusses the recent progression in AKR study in mammalian tumors, focusing on prostate and breast cancer.
Keywords
- Aldo-Keto Reductase
- Aldose ReductaseLike-1/Aldo-Keto Reductase Family 1 member 10
- Antitumor agents
- Hepatocellular Carcinoma
- Lung Cancer
- Prostate Cancer
- Breast Cancer
- Carbonyl Metabolism
- and Aflatoxin B1
- Review